Graviti Pharmaceuticals recalled 46,512 bottles of Bupropion Hydrochloride Extended-Release Tablets on September 15, 2025. The recall stems from failed tablet specifications that could affect safety and efficacy. The product was distributed to pharmacies nationwide.
Failed Tablet/Capsule Specifications
Consumers and healthcare providers should stop using this product immediately. Contact Graviti Pharmaceuticals Private Limited or your healthcare provider for guidance. Notification method: Letter
The recall includes Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg, sold in 30-count bottles. The affected batch number is BPB124341A with an expiration date of October 2026.
The recalled tablets failed to meet established specifications, posing a risk to consumers who may rely on them for treatment. The specific nature of the failure has not been detailed.
No injuries or incidents related to this product have been reported at this time. The recall is classified as Class II, indicating a potential for serious health issues.
Consumers should stop using the recalled tablets immediately. Contact Graviti Pharmaceuticals or your healthcare provider for guidance on next steps.
For more information, contact Graviti Pharmaceuticals at the provided FDA link or consult your healthcare provider.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.